Quantcast

Merck’s Keytruda showed increase in pathological complete response with chemotherapy versus neoadjuvant therapy chemotherapy in early-stage triple-negative breast cancer

Merck’s trial of Keytruda plus chemotherapy, followed by adjuvant Keytruda as monotherapy, which was granted Breakthrough Therapy designation (BTD) by the U.S. Food and Drug Administration (FDA) for the neoadjuvant treatment of patients with high-risk, early-stage TNBC plus chemotherapy, resulted in a statistically significant increase in pathological complete response (pCR) versus chemotherapy.

Read more

Noxxon shows at ESMO pembrolizumab’s potential to target the tumor microenvironment in a Keytruda combination trial

Noxxon will present latest Clinical data from phase 1/2 NOX-A12 / Keytruda combination trial at the ESMO congress on Monday at 09.00 A.M., which shows that the combination of NOX-A12 and pembrolizumab induced an immune response, stable disease in 25% of patients and prolonged time on treatment vs. prior therapy for 35% of patients.

Read more

Merck, Eisai welcome final study results for Keytruda/Lenvima combo treatment in advanced endometrial cancer presented at ESMO 2019 congress

“The results of this Keytruda plus Lenvima study are a welcome development in the treatment of women with advanced endometrial cancer, a patient group with an unmet medical need,” said Dr. Vicky Makker, principal investigator and medical oncologist, Memorial Sloan Kettering Cancer Center.

Read more

Five-Year Outcomes for Opdivo (nivolumab) in Combination with Yervoy (ipilimumab) Demonstrate Durable Long-Term Survival Benefits in Patients with Advanced Melanoma

Bristol-Myers squib’s Opdivo combined with Yervoy resulted in 52% of patients with being alive at five years, while 74% of patients treated with Opdivo plus Yervoy who were alive at five years remained treatment-free, the longest follow-up to date results for dual Immuno-Oncology (I-O) therapy in a Phase 3, randomized, controlled trial showed.

Read more

Seattle Genetics, Astellas Phase 1 Trial of Investigational Agent Enfortumab Vedotin plus Pembrolizumab met outcomes: 71% patients confirm response.

Seattle Genetics, and Astellas Pharma’s study met outcomes for safety and 71 Percent of patients with locally advanced or metastatic urothelial (bladder) cancer had a confirmed response, the companies presented Saturday at ESMO Congress in Barcelona.

Read more